Scientific results are shown on posters at congresses

Generally, RABBIT shows biologic DMARDs to be effective, safe and well tolerated in daily rheumatologic care. Used by experienced rheumatologists, they are a safe treatment option for patients with rheumatoid arthritis, who do not respond adequately to non-biologic DMARDs.

In practice, biologic DMARDs are not prescribed until non-biologic DMARDs fail or are not tolerated. That means that patients for whom biologic DMARDs are indicated differ systematically from patients who are treated with non-biologic DMARDs. Therefore, highly sophisticated statistical methods are required to compare patients on biologic and non-biologic DMARDs.

Here, we will give a short insight into our published results: Original publications

Eingeschlossene Patienten: 21.393 (Stand 1. August 2022) 
Amgevita® (Adalimumab)153
Benepali® (Etanercept)940
Cimzia® (Certolizumab)986
Enbrel® (Etanercept)2868
Erelzi® (Etanercept)406
Flixabi® (Infliximab)9
Hulio® (Adalimumab)136
Humira® (Adalimumab)2903
Hyrimoz® (Adalimumab)135
Idacio® (Adalimumab)41
Imraldi® (Adalimumab)150
Inflectra™ (Infliximab)16
Jyseleca® (Filgotinib)63
Kevzara® (Sarilumab)178
Kineret® (Anakinra)89
MabThera® (Rituximab)1459
Nepexto® (Etanercept)25
Olumiant® (Baricitinib)496
Orencia® (Abatacept)912
Remicade® (Infliximab)762
Remsima® (Infliximab)12
Rinvoq® (Upadacitinib)241
Rixathon® (Rituximab)18
RoActemra® (Tocilizumab)1335
Ruxience® (Rituximab)1
Simponi® (Golimumab)453
Xeljanz® (Tofacitinib)387
Zessly® (Infliximab)2